Pulse of the Healthcare Sector: Complementary Research on Sorrento, Aoxing, Neuralstem, ICU Medical and Avalanche Biotechnologies
NEW YORK, May 11, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Sorrento Therapeutics, Inc. (NASDAQ: SRNE), Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN), Neuralstem, Inc. (NYSE MKT: CUR), ICU Medical, Inc. (NASDAQ: ICUI), and Avalanche Biotechnologies, Inc. (NASDAQ: AAVL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
SRNE Research Report: ( http://get.analystsreview.com/pdf/?c=Sorrento&d=11-May-2015&s=SRNE ),
AXN Research Report: ( http://get.analystsreview.com/pdf/?c=Aoxing&d=11-May-2015&s=AXN ),
CUR Research Report: ( http://get.analystsreview.com/pdf/?c=Neuralstem&d=11-May-2015&s=CUR ),
ICUI Research Report: ( http://get.analystsreview.com/pdf/?c=ICU%20Medical&d=11-May-2015&s=ICUI ),
AAVL Research Report: ( http://get.analystsreview.com/pdf/?c=Avalanche%20Biotechnologies&d=11-May-2015&s=AAVL ).
============
--
Analyst Update: Financial and Operational Results, Clinical Trial Results, Appointments and Agreements
U.S. stocks advanced sharply on Friday, after stronger employment data for April suggested the US economy is gaining traction again. The Dow Jones Industrial Average rose 1.49%, to close at 18,191.11, the S&P 500 gained 1.35%, to 2,116.10, and the NASDAQ Composite finished the session at 5,003.55, up 1.17%. European stocks rallied on Friday, lifted by the UK election results, which showed the Conservative Party unexpectedly sweeping into power again. Germany's DAX 30 rose 2.65%, France's CAC 40 advanced 2.48%, and the London's FTSE 100 closed 2.32% higher on Friday. Meanwhile, Asian markets surged on Friday after losing ground in the last few days. The Shanghai Composite, Japan's Nikkei, and Hong Kong's Hang Seng all posted gains on Friday.
On May 4, 2015, Sorrento Therapeutics, Inc. announced results from recently analyzed pharmacokinetic (PK) data from its TRIBECA (TRIal establishing BioEquivalence between Cynviloq™ and Albumin-bound paclitaxel) registrational trial, which were positive. Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel.
Aoxing Pharmaceutical Company, Inc. reported a net income of $0.60 million for the second quarter 2015 (period ended December 31, 2014) as against a net loss of $1.92 million reported by the Company in the previous year quarter. During the quarter, the sales of the Company increased to $6.43 million from $3.47 million in the quarter ended December 31, 2013.
On May 6, 2015, Neuralstem, Inc. announced that it has appointed Jonathan Lloyd Jones as the CFO of the organization, effective May 18, 2015. According to the Company, Mr. Lloyd Jones brings to the position more than 25 years of corporate finance and business development experience. Most recently, Mr. Lloyd Jones served as CFO at Columbia Laboratories (Juniper Pharmaceuticals).
On May 5, 2015, ICU Medical, Inc. announced its financial results for the first quarter of 2015. The Company reported revenues of $81.5 million for Q1 FY15, compared to $73.2 million in the same period last year. The net income figure for the period came in at $9.7 million, or $0.60 per diluted share, versus reported net income of $6.7 million, or $0.43 per diluted share, for the first quarter of 2014.
Avalanche Biotechnologies, Inc. recently announced that it has entered into an exclusive license agreement with the University of Washington in Seattle to develop products based on the Company's proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), which otherwise more commonly is known as red-green color blindness.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article